Lexicon Pharmaceuticals (LXRX) to Release Quarterly Earnings on Tuesday

Lexicon Pharmaceuticals (NASDAQ:LXRX) will be issuing its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX opened at $1.27 on Monday. The company has a 50-day moving average of $1.67 and a two-hundred day moving average of $1.75. The stock has a market cap of $312.72 million, a price-to-earnings ratio of -1.63 and a beta of 1.24. The company has a debt-to-equity ratio of 0.41, a current ratio of 11.51 and a quick ratio of 11.49. Lexicon Pharmaceuticals has a one year low of $0.92 and a one year high of $3.73.

Analysts Set New Price Targets

LXRX has been the subject of a number of recent analyst reports. Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, October 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Lexicon Pharmaceuticals in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Lexicon Pharmaceuticals has an average rating of “Hold” and an average target price of $6.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.